Miami, Mar 17: Cancer treatment is often described as a race against time. But for many patients, chemotherapy-induced thrombocytopenia (CIT) creates a roadblock—forcing clinicians to delay or reduce treatment. A new phase 3 clinical trial published in The New England Journal of Medicine suggests there may now be a way to keep that journey moving forward.
In the international RECITE trial, investigators found that romiplostim, a thrombopoietin receptor agonist, significantly reduced chemotherapy dose delays and reductions in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The findings mark a potential shift in how oncologists manage one of chemotherapy’s most stubborn complications—and how they preserve the intensity of cancer care when it matters most.
Platelets are a key initial component in the response to bleeding, rushing in to stop the bleeding and maintain vascular integrity. Chemotherapy, however, can decimate these cells, leaving patients vulnerable to bleeding and forcing clinicians to reduce or delay treatment. For patients with advanced colorectal, gastroesophageal or pancreatic cancers—where timing and dose intensity are closely tied to outcomes—those interruptions can have cascading negative effects.
“CIT doesn’t just complicate treatment; it compromises it,” said senior author, Gerald A. Soff, M.D., chief of Classical Hematology at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. “When we reduce chemotherapy dose intensity, we may be giving cancer more opportunity to adapt and persist.”
Until now, there have been no widely approved therapies specifically indicated to treat CIT, leaving clinicians with few options beyond supportive care or chemotherapy modification.
The RECITE trial enrolled 165 patients with persistent CIT who were receiving oxaliplatin-based multiagent chemotherapy. Participants were randomized in a 2:1 ratio to receive either romiplostim or placebo over three chemotherapy cycles. The primary endpoint was pragmatic and clinically meaningful: whether patients could avoid CIT-related chemotherapy dose reductions, delays, omissions, or discontinuations during cycles two and three.
The results were striking. Eighty‑four percent of patients receiving romiplostim completed chemotherapy without dose modification, compared with only 36 percent in the placebo group. In effect, romiplostim dramatically improved the bone marrow’s ability to produce platelets so treatment could proceed as planned.
Adverse events were largely consistent with expected chemotherapy effects. Importantly, thromboembolic events were infrequent, occurring in only a small percentage of patients receiving romiplostim, with none reported in the placebo arm.
Oncology research has long shown that relative dose intensity—delivering the right amount of chemotherapy on schedule—can influence survival and disease control. Interruptions may give tumors time to escape the benefit of the cancer treatment. CIT is one of the most common causes of chemotherapy interruptions.
“From a hematology standpoint, this study confirms a very effective treatment for CIT in patients with gastrointestinal cancers,” Dr. Soff said. “That’s a meaningful advance for patients whose chance for successful cancer treatment depends on staying on track.”
By enabling patients to maintain chemotherapy intensity, romiplostim may help oncologists avoid the difficult trade-off between bleeding risk and cancer control—though longer-term outcomes will continue to be studied.
As investigators continue to explore how best to deploy this therapy across cancer types and treatment regimens, the RECITE trial offers a clear signal: protecting platelet production can help protect the integrity of cancer care itself.
“Keeping patients on treatment, safely and effectively, is the goal,” Dr. Soff added. “This study gives us a new tool to help do exactly that.”
